NCT00168896Unknown2 期
A Randomised Phase II/III Study to Compare the Combination of Carboplatin Plus Irinotecan Vs. the Combination of Carboplatin Plus Etoposide for SCLC in Extensive Disease Stage
适应症
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 286
- 试验地点
- 2
- 主要终点
- Primary Endpoint:
研究概览
简要总结
Comparison of two combination chemotherapies in the treatment of patients with SLCL
详细描述
Comparison of two combination chemotherapies in the treatment of patients with SLCL
The combination chemotherapies for this study are Carboplatin plus Irinotecan versus Carboplatin plus Etoposide.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •cytological or histological proven SCLC Stage I or II at 1st diagnosis
- •no prior chemotherapy
- •measurable tumor disease
- •karnofsky performance 70
排除标准
- •second malignancy ( except basal cell carcinoma, CA in situ Cervix uteri)
- •chronic diarrhea, obstructive bowel syndrome
结局指标
主要结局
Primary Endpoint:
Documentation of the remission rate ( Phase II)
Determination of progress free time (Phase III)
次要结局
- Secondary Endpoint:
- Documentation of progress free time (Phase II)
- Documentation of objective remission rate ( Phase III)
- Documentation of 1-year survival rate
- Documentation of safety of the drug combination
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
不适用
Phase 2 study of combination chemotherapy(VBL/PSL, MTX, 6MP) in patients with primary untreated adult langerhans cell histiocytosisadult langerhans cell histiocytosisJPRN-UMIN000006016Department of Hematology, International Medical Center, Saitama Medical University5
已完成
2 期
Study for Therapy of Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) With Cisplatin / Docetaxel or Oxaliplatin / DocetaxelNon Small Cell Lung CancerNCT01222312Krankenhaus Nordwest88
进行中（未招募）
3 期
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)Limited Stage Lung Small Cell CarcinomaStage I Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8NCT03811002National Cancer Institute (NCI)544
已完成
3 期
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's LymphomaStage III Grade 1 Follicular LymphomaStage III Grade 2 Follicular LymphomaStage III Grade 3 Follicular LymphomaStage III Small Lymphocytic LymphomaStage IV Grade 1 Follicular LymphomaStage IV Grade 2 Follicular LymphomaStage IV Grade 3 Follicular LymphomaStage IV Small Lymphocytic LymphomaNCT00003204National Cancer Institute (NCI)515
已完成
2 期
Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive RhabdomyosarcomaAlveolar Childhood RhabdomyosarcomaEmbryonal Childhood RhabdomyosarcomaEmbryonal-botryoid Childhood RhabdomyosarcomaPreviously Treated Childhood RhabdomyosarcomaRecurrent Childhood RhabdomyosarcomaNCT00025363National Cancer Institute (NCI)150